These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 2189953

  • 1. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
    Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F.
    J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
    [Abstract] [Full Text] [Related]

  • 2. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Zigelboim J.
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [Abstract] [Full Text] [Related]

  • 3. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
    Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB.
    J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
    [Abstract] [Full Text] [Related]

  • 4. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, Horton MC, McVey L, Morris J, Weiss RJ.
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
    Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P.
    Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
    [Abstract] [Full Text] [Related]

  • 8. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 9. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 10. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Clin Oncol; 1992 Sep; 10(9):1479-84. PubMed ID: 1517791
    [Abstract] [Full Text] [Related]

  • 11. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M, Chapman D, Saigo P.
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ, Braly P, Cecchi G, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Parker P, Stein A, Cho J, Smith E, Coluzzi P, Najera L, Johnson D, Womack E, Doroshow JH.
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [Abstract] [Full Text] [Related]

  • 13. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB.
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [Abstract] [Full Text] [Related]

  • 14. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
    Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD.
    Gynecol Oncol; 1992 Apr; 45(1):3-8. PubMed ID: 1601332
    [Abstract] [Full Text] [Related]

  • 15. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F, Schneider J, Markman M, Reichman BS, Venkatraman E, Barakat R, Almadrones L, Spriggs D.
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.
    Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R.
    Anticancer Res; 1991 Oct; 11(4):1641-3. PubMed ID: 1746921
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.